Tradewinds LLC. Acquires Shares of 20,000 Neuronetics, Inc. (NASDAQ:STIM)

Tradewinds LLC. bought a new position in shares of Neuronetics, Inc. (NASDAQ:STIM) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 20,000 shares of the company’s stock, valued at approximately $32,000. Tradewinds LLC. owned about 0.07% of Neuronetics at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in STIM. David J Yvars Group boosted its stake in Neuronetics by 47.1% during the fourth quarter. David J Yvars Group now owns 46,325 shares of the company’s stock worth $75,000 after buying an additional 14,825 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Neuronetics by 10,954.1% during the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after acquiring an additional 54,442 shares during the last quarter. Finally, HighTower Advisors LLC grew its holdings in shares of Neuronetics by 55.5% in the third quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock valued at $187,000 after purchasing an additional 87,816 shares during the period. 53.59% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group boosted their target price on shares of Neuronetics from $5.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, March 5th.

Insider Activity

In related news, EVP William Andrew Macan sold 12,175 shares of the business’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total value of $46,630.25. Following the sale, the executive vice president now owns 388,647 shares in the company, valued at approximately $1,488,518.01. The trade was a 3.04 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Stephen Furlong sold 14,836 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $3.28, for a total value of $48,662.08. Following the transaction, the chief financial officer now owns 482,572 shares of the company’s stock, valued at $1,582,836.16. This trade represents a 2.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 100,369 shares of company stock valued at $358,929. Company insiders own 9.80% of the company’s stock.

Neuronetics Stock Performance

NASDAQ STIM opened at $3.78 on Wednesday. The stock has a fifty day simple moving average of $4.08 and a 200-day simple moving average of $2.19. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90. The stock has a market cap of $114.72 million, a PE ratio of -3.07 and a beta of 2.07. Neuronetics, Inc. has a twelve month low of $0.52 and a twelve month high of $5.92.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.